ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,798 | -23.4% | 1,481 | -0.9% | 0.01% | -10.0% |
| Q2 2023 | $68,918 | +15.0% | 1,494 | 0.0% | 0.01% | +11.1% |
| Q1 2023 | $59,909 | +85484.3% | 1,494 | -1.2% | 0.01% | -18.2% |
| Q4 2022 | $70 | -99.9% | 1,512 | 0.0% | 0.01% | +10.0% |
| Q3 2022 | $63,000 | -30.0% | 1,512 | 0.0% | 0.01% | -33.3% |
| Q2 2022 | $90,000 | -53.8% | 1,512 | -43.6% | 0.02% | -37.5% |
| Q1 2022 | $195,000 | -0.5% | 2,682 | +14.9% | 0.02% | +9.1% |
| Q4 2021 | $196,000 | -19.3% | 2,334 | -13.5% | 0.02% | -26.7% |
| Q3 2021 | $243,000 | -5.4% | 2,699 | 0.0% | 0.03% | 0.0% |
| Q2 2021 | $257,000 | -18.9% | 2,699 | -3.2% | 0.03% | -23.1% |
| Q1 2021 | $317,000 | -4.2% | 2,788 | +16.5% | 0.04% | -4.9% |
| Q4 2020 | $331,000 | +68.0% | 2,393 | 0.0% | 0.04% | +46.4% |
| Q3 2020 | $197,000 | -58.6% | 2,393 | -68.1% | 0.03% | -65.9% |
| Q1 2016 | $476,000 | – | 7,512 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |